The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Highlights in multiple myeloma at EHA 2022
In this video, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France shares some key updates in multiple myeloma from the 2022 EHA meeting, drawing focus on the excitement surrounding bispecific antibodies. Prof. Mohty first discusses the impressive response rates observed with bispecifics in heavily pre-treated patients, and further highlights some findings from the MajesTEC-1 trial (NCT04557098). To conclude, Prof. Mohty comments on novel antigens being investigated and the promising results observed with anti-BCMA therapies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
